ROCHESTER, Minnesota, July 8 — For a field that began with a single question about aging cells, senolytic research has come a remarkably long way in a decade and a half. The science, which focuses on drugs that selectively eliminate senescent cells—those worn-out cells that accumulate as we age and drive inflammation and disease—is now at a point where real human trials have been conducted, and the results are beginning to shape what could become a new class of treatments.
The story starts in 2011, when Jan van Deursen at the Mayo Clinic published a landmark study. He and his team showed that removing senescent cells in mice delayed age-related kidney dysfunction.
It was a proof of concept that suggested aging itself might be modifiable at the cellular level. Four years later, in 2015, a team led by James Kirkland, also at the Mayo Clinic, identified the first senolytic drugs: dasatinib and quercetin. These compounds were shown to reduce the burden of senescent cells in mice.
The work was a major step, turning a theoretical idea into something that could be tested in living organisms. A follow-up study in 2018, again from Kirkland’s group, demonstrated that a combination of dasatinib and quercetin improved physical function in mice.
That finding was important because it moved beyond simply clearing cells—it showed measurable benefits in how the animals actually moved and performed. The first human clinical trial of senolytics was conducted at the Mayo Clinic and published in 2019. It involved 14 patients with idiopathic pulmonary fibrosis, a progressive lung disease with no cure.
The results showed improved physical function in those patients. For a field that had been largely confined to animal models, this was a watershed moment. But not every senolytic trial has been a success.
Unity Biotechnology, a company founded in 2011, initiated a phase 2 clinical trial for its senolytic drug UBX0101 in 2019. The target was osteoarthritis of the knee, a condition where senescent cells are thought to play a role in joint pain and cartilage breakdown.
In 2020, the trial failed to meet its primary endpoint. It was a sobering reminder that moving from the lab to the clinic is never straightforward.
The mechanism behind the science
Senescent cells are sometimes called zombie cells. They stop dividing but don’t die off as they should. Instead, they linger and secrete inflammatory signals that damage surrounding tissue.
As we age, these cells accumulate in organs and joints, contributing to everything from kidney dysfunction to arthritis to lung disease. Senolytics work by targeting the pathways that keep these zombie cells alive.
By clearing them, the drugs aim to reduce the inflammatory burden and allow the body to function more like it did when it was younger. The approach is fundamentally different from treating a single disease—it targets a root cause of many age-related conditions. The National Institute on Aging has recognized the potential.
Through its Division of Aging Biology, the institute has funded senolytic research since 2015. That federal support has been critical for moving the science forward, especially given the high cost and risk of early-stage drug development.
What comes next
The field is still young. The 2019 human trial was small, with only 14 patients. The Unity Biotechnology failure in 2020 was a setback, but it also provided valuable data about what does and does not work.
Researchers are now designing new compounds and testing different combinations of existing drugs. For the scientists at Mayo Clinic, the work continues.
The original team that identified dasatinib and quercetin is still refining the approach, looking for ways to make senolytics more effective and less toxic. The goal is to find drugs that can be given intermittently—perhaps once a month or even less often—to keep senescent cells at bay without causing side effects. For patients and families watching this field, the progress is real but measured.
No senolytic drug has yet been approved for any condition. But the fact that a human trial has shown improved physical function in a devastating disease like idiopathic pulmonary fibrosis is a milestone that should not be underestimated.
The story of senolytics is still being written. The science is rigorous, the funding is in place, and the early results are promising. What remains is the hard work of turning those results into treatments that can help people live healthier, longer lives. Consult your doctor for medical advice.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Senolytics: Clearing Senescent Cells to Combat Age-Related Disease”, “description”: “ROCHESTER, Minnesota, July 8 — For a field that began with a single question about aging cells, senolytic research has come a remarkably long way…”, “datePublished”: “2026-07-08T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “James Roberto”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
